Physician Views: Repatha recommended for European approval - how will EU5 cardiologists utilise the PCSK9 inhibitor class?

Physician Views: Repatha recommended for European approval - how will EU5 cardiologists utilise the PCSK9 inhibitor class?

Code: FW-20150507 | Published: May-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






Amgen and Sanofi/Regeneron Pharmaceuticals may be locked in one of the most intriguing US drug regulatory races of recent memory, but it is the European Medicines Agency that has provided a first definitive regulatory action for the PCSK9 inhibitor class by recommending approval of Amgens Repatha.

The EMA has recommended approval of a broad label for Repatha in Europe, which includes those patients with mixed dyslipidaemia who are unable to reach LDL-cholesterol reduction goals with statin therapy or whom are intolerant to statins. Furthermore, Phase III data for Repatha has demonstrated LDL-C reductions of 46 percent to 64 percent from baseline at week 12 in various patient populations with hyperlipidaemia.

How cardiologists utilise this drug class is, however, a very different matter. Data from ongoing outcomes studies - due to be published in 2017/18 - are expected to shape the longer-term uptake of the PCSK9 inhibitors, while other factors - such as pricing and access - will also play a prominent role on the European landscape (ViewPoints: Europe provides positive regulatory momentum for PCSK9 inhibitor class, but regional cardiologists likely to prescribe less than US counterparts).









To better ascertain sentiment towards the PCSK9 inhibitor class, FirstWord Pharma is asking cardiologists based in France, Germany, Italy, Spain and the UK the following questions...


- It has been estimated that the PCSK9 inhibitors will cost between $5000 and $10000 per patient per year in the US market; even factoring a likely price discount in Europe, how significant a role do you expect price to play in limiting the use of these drugs?
- Prior to the availability of cardiovascular outcomes data for the PCSK9 inhibitor class (expected in 2017/18), what level of usage do you anticipate for the treatment of patients with HeFH or HoFH?
- Prior to the availability of cardiovascular outcomes data for the PCSK9 inhibitor class, what level of usage do you anticipate for the treatment of patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or patients who are statin intolerant?
- How significant a role do you expect an initial lack of cardiovascular outcomes data for this drug class to limit usage in statin-intolerant/LDL-C target non-achiever patients?
- How much increased pressure do you expect to be under to ensure that patients have received the correct dosing/treatment with statins and/or other available therapies once the PCSK9 inhibitor class becomes available?


Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients